Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the importance of evaluating patient-reported outcomes in myeloproliferative neoplasms (MPNs), and further highlights the value of implementing questionnaires and other methods of assessing these outcomes in clinical trials and in clinical practice. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.